Last reviewed · How we verify
UFT adjuvant chemotherapy
UFT is a combination of uracil and tegafur (a prodrug of fluorouracil) that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells.
UFT is a combination of uracil and tegafur (a prodrug of fluorouracil) that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells. Used for Adjuvant chemotherapy for colorectal cancer, Gastric cancer adjuvant treatment.
At a glance
| Generic name | UFT adjuvant chemotherapy |
|---|---|
| Also known as | Adjuvant chemotherapy with tegafur-uracil |
| Sponsor | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan |
| Drug class | Antimetabolite chemotherapy |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
UFT combines uracil with tegafur, a prodrug that is metabolized to fluorouracil (5-FU), a classic antimetabolite chemotherapy agent. The fluorouracil component inhibits thymidylate synthase, blocking dTMP synthesis and disrupting DNA replication in rapidly dividing cancer cells. Uracil acts as a modulator to enhance and prolong the cytotoxic effects of fluorouracil.
Approved indications
- Adjuvant chemotherapy for colorectal cancer
- Gastric cancer adjuvant treatment
Common side effects
- Diarrhea
- Nausea and vomiting
- Bone marrow suppression
- Hand-foot syndrome
- Stomatitis
Key clinical trials
- A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (PHASE3)
- A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA (PHASE3)
- A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors (PHASE1)
- Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery (PHASE3)
- Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery
- A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF) (PHASE3)
- Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2) (PHASE3)
- S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: